Inside Health

The first drugs to slow Alzheimer's progression have been making headlines around the world. For researchers in the field, the arrival of these two therapies called Lecanemab and Donanemab is testament to decades of advancements in the field of Alzheimer's research because for the first time they go further than modifying the symptoms and have been shown in trials to slow down cognitive decline. For patients and families these treatments offer hope that the amount of quality time they'll have together could be lengthened. Around the world regulatory bodies are weighing up their effectiveness, safety and cost. In the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lecanemab and Donanemab for use but the National Institute for Health and Care Excellence (NICE) rejected them for use in the NHS on the basis the benefit to patients did not outweight the cost, although they could still be available privately.Presenter James Gallagher examines the decision with Professor of Public Health Carol Brayne from the University of Cambridge and neuroscientist Professor Tara Spires-Jones from the University of Edinburgh. Then, looking forward, he meets scientists searching for future treatments including Dr Emma Mead, chief scientist at the Alzheimer's UK Drug Discovery Institute at the University of Oxford, Dr Ashvini Keshavan, co-lead of University College London's ADAPT blood biomarker trial, Selina Wray, Professor of Molecular Neuroscience and Alzheimer's Research UK Senior Research Fellow at University College London, and UK Dementia Research Institute Emerging Leader Dr Claire Durrant.This programme was produced in partnership with The Open University.Presenter: James Gallagher Producer: Tom Bonnett Editor: Holly Squire

Have you ever thought about how you breathe? For many of us, the 20,000+ breaths we take each day go underneath our conscious awareness. But every now and then, a short-lived spout or a chronic case of breathlessness can remind us just how vital good breathing is for our health. But can we all breathe “better”? Some wellness trends suggest so... James Gallagher gets to grips with mouth-taping: the practice of taping the mouth shut during the night to promote exclusive ‘nasal breathing’. Many claim it has improved their sleep, their athletic performance and even given them a more chiselled jaw. Ken O’Halloran, professor of physiology at University College Cork, explains what research has been done looking into this trend and warns about when taping might do more harm than good. James also visits The Coliseum in Covent Garden to hear how an operatic training programme has improved the quality of life for people living with Long-COVID. ENO Breathe, designed by The English National Opera and Imperial College Healthcare NHS Trust, has seen 4000 people learn to breathe like a classical singer to help them handle breathlessness. Creative director, Suzi Zumpe, and respiratory registrar, Keir Philip, talk through the programme and its impacts. Finally, could taking consciousness control of our breathing for a short time each day improve our health? Guy Fincham, researcher at the University of Sussex, dives into his PhD research on breathwork, including his initial studies looking at who might benefit from these practices. Presenter: James Gallagher Producer: Julia Ravey Content Editor: Holly Squire Studio Engineer: Giles Aspen Production Coordinator: Ismael Soriano This programme was produced in partnership with The Open University.

There are so many campaigns now to stop stigma and embarrassment - from Davina McCall talking about the menopause to Idris Elba campaigning for black men to get their prostate checked. And when we asked for your stories of how embarrassment impacts your health, our inbox was flooded with stories of incontinence, IBS, genital problems, skin issues, fertility troubles, fatty lumps and more - along with the huge and varied ways these issues are affecting your lives. So, how does embarrassment affect how we behave regarding our health, how can doctors and our health service adapt to alleviate it, and do awareness campaigns really help? To discuss James Gallagher is joined by:Dr Margaret McCartney, GP Dr Vanessa Apea, consultant in sexual health at Barts Health NHS Trust and Medical Director at Preventx Professor Ruth Parry, communications expert who studies clinician-patient interactions about sensitive issues. Plus, James gets some top tips to help alleviate embarrassment when talking to your doctor. Presenter: James Gallagher Producer: Hannah Robins Content Editor: Holly Squire Production Coordinator: Ismael SorianoThis programme was produced in partnership with The Open University.

If you have a rare genetic disorder, new technology that allows your genetic code to be analysed means you could have a diagnosis within weeks. Before, people with rare diseases would often go their entire lives without a diagnosis. It's a revolutionary advancement but does it change how patients are treated or help improve their wellbeing?Presenter James Gallagher meets Lisa whose daughter Jaydi was born with a rare genetic disease that affects her growth, speech, eyesight and a number of other conditions. We hear the story of Lisa and Jaydi's journey to diagnosis through Exeter University's Deciphering Developmental Disorders (DDD) study, and how it changed the course of Jaydi's life.Her clinician, Consulatant Clinical Geneticist Dr Emma Kivuva, tells James how the diagnosis impacted on the care they offered and Dr Caroline Wright, Genetics & Genomics Theme Lead on the DDD study explains how they are measuring the effect of diagnosis on patient treatment and wellbeing.This programme was produced in partnership with The Open University.Presenter: James Gallagher Producer: Tom Bonnett Editor: Holly Squire